Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 41 entries
Sorted by: Best Match Show Resources per page
Current trends in robotic surgery for otolaryngology.

Current otorhinolaryngology reports

Byrd JK, Duvvuri U.
PMID: 24069577
Curr Otorhinolaryngol Rep. 2013 Sep 01;1(3):153-157. doi: 10.1007/s40136-013-0025-6.

As minimally invasive surgery has become common in head and neck surgery, the role of robotic surgery has expanded from thyroid surgery and transoral robotic surgery (TORS) of the oropharynx and supraglottic to other areas. Surgeons have advanced the...

Cite
Byrd JK, Duvvuri U. Current trends in robotic surgery for otolaryngology. Curr Otorhinolaryngol Rep. 2013;1(3):153-157doi: 10.1007/s40136-013-0025-6.
Byrd, J. K., & Duvvuri, U. (2013). Current trends in robotic surgery for otolaryngology. Current otorhinolaryngology reports, 1(3), 153-157. https://doi.org/10.1007/s40136-013-0025-6
Byrd, J Kenneth, and Duvvuri, Umamaheswar. "Current trends in robotic surgery for otolaryngology." Current otorhinolaryngology reports vol. 1,3 (2013): 153-157. doi: https://doi.org/10.1007/s40136-013-0025-6
Byrd JK, Duvvuri U. Current trends in robotic surgery for otolaryngology. Curr Otorhinolaryngol Rep. 2013 Sep 01;1(3):153-157. doi: 10.1007/s40136-013-0025-6. PMID: 24069577; PMCID: PMC3779610.
Copy Download .nbib Format: NLM
Cisplatin-Based Chemotherapy Options for Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck.

Clinical medicine insights. Therapeutics

Pendleton KP, Grandis JR.
PMID: 24273416
Clin Med Insights Ther. 2013;2013(5). doi: 10.4137/CMT.S10409.

Recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is a devastating malignancy with a poor prognosis. Treatment is limited to chemotherapeutic approaches. Cisplatin is an established and effective treatment for R/M HNSCC, and many studies have...

Cite
Pendleton KP, Grandis JR. Cisplatin-Based Chemotherapy Options for Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck. Clin Med Insights Ther. 2013;2013(5)doi: 10.4137/CMT.S10409.
Pendleton, K. P., & Grandis, J. R. (2013). Cisplatin-Based Chemotherapy Options for Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck. Clinical medicine insights. Therapeutics, 2013(5), . https://doi.org/10.4137/CMT.S10409
Pendleton, Kelsey P, and Grandis, Jennifer R. "Cisplatin-Based Chemotherapy Options for Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck." Clinical medicine insights. Therapeutics vol. 2013,5 (2013). doi: https://doi.org/10.4137/CMT.S10409
Pendleton KP, Grandis JR. Cisplatin-Based Chemotherapy Options for Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck. Clin Med Insights Ther. 2013;2013(5). doi: 10.4137/CMT.S10409. PMID: 24273416; PMCID: PMC3835153.
Copy Download .nbib Format: NLM
Mechanism of action of selective inhibitors of IL-6 induced STAT3 pathway in head and neck cancer cell lines.

Journal of chemical biology

Sen M, Johnston PA, Pollock NI, DeGrave K, Joyce SC, Freilino ML, Hua Y, Camarco DP, Close DA, Huryn DM, Wipf P, Grandis JR.
PMID: 28684999
J Chem Biol. 2017 May 11;10(3):129-141. doi: 10.1007/s12154-017-0169-9. eCollection 2017 Jul.

Studies indicate that elevated interleukin-6 (IL-6) levels engage IL6Rα-gp130 receptor complexes to activate signal transducer and activator of transcription 3 (STAT3) that is hyperactivated in many cancers including head and neck squamous cell carcinoma (HNSCC). Our previous HCS campaign...

Cite
Sen M, Johnston PA, Pollock NI, et al. Mechanism of action of selective inhibitors of IL-6 induced STAT3 pathway in head and neck cancer cell lines. J Chem Biol. 2017;10(3):129-141doi: 10.1007/s12154-017-0169-9.
Sen, M., Johnston, P. A., Pollock, N. I., DeGrave, K., Joyce, S. C., Freilino, M. L., Hua, Y., Camarco, D. P., Close, D. A., Huryn, D. M., Wipf, P., & Grandis, J. R. (2017). Mechanism of action of selective inhibitors of IL-6 induced STAT3 pathway in head and neck cancer cell lines. Journal of chemical biology, 10(3), 129-141. https://doi.org/10.1007/s12154-017-0169-9
Sen, Malabika, et al. "Mechanism of action of selective inhibitors of IL-6 induced STAT3 pathway in head and neck cancer cell lines." Journal of chemical biology vol. 10,3 (2017): 129-141. doi: https://doi.org/10.1007/s12154-017-0169-9
Sen M, Johnston PA, Pollock NI, DeGrave K, Joyce SC, Freilino ML, Hua Y, Camarco DP, Close DA, Huryn DM, Wipf P, Grandis JR. Mechanism of action of selective inhibitors of IL-6 induced STAT3 pathway in head and neck cancer cell lines. J Chem Biol. 2017 May 11;10(3):129-141. doi: 10.1007/s12154-017-0169-9. eCollection 2017 Jul. PMID: 28684999; PMCID: PMC5480263.
Copy Download .nbib Format: NLM
Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing.

Nature communications

Kürten CHL, Kulkarni A, Cillo AR, Santos PM, Roble AK, Onkar S, Reeder C, Lang S, Chen X, Duvvuri U, Kim S, Liu A, Tabib T, Lafyatis R, Feng J, Gao SJ, Bruno TC, Vignali DAA, Lu X, Bao R, Vujanovic L, Ferris RL.
PMID: 34921143
Nat Commun. 2021 Dec 17;12(1):7338. doi: 10.1038/s41467-021-27619-4.

Head and neck squamous cell carcinoma (HNSCC) is characterized by complex relations between stromal, epithelial, and immune cells within the tumor microenvironment (TME). To enable the development of more efficacious therapies, we aim to study the heterogeneity, signatures of...

Cite
Kürten CHL, Kulkarni A, Cillo AR, et al. Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing. Nat Commun. 2021;12(1):7338doi: 10.1038/s41467-021-27619-4.
Kürten, C. H. L., Kulkarni, A., Cillo, A. R., Santos, P. M., Roble, A. K., Onkar, S., Reeder, C., Lang, S., Chen, X., Duvvuri, U., Kim, S., Liu, A., Tabib, T., Lafyatis, R., Feng, J., Gao, S. J., Bruno, T. C., Vignali, D. A. A., Lu, X., Bao, R., Vujanovic, L., & Ferris, R. L. (2021). Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing. Nature communications, 12(1), 7338. https://doi.org/10.1038/s41467-021-27619-4
Kürten, Cornelius H L, et al. "Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing." Nature communications vol. 12,1 (2021): 7338. doi: https://doi.org/10.1038/s41467-021-27619-4
Kürten CHL, Kulkarni A, Cillo AR, Santos PM, Roble AK, Onkar S, Reeder C, Lang S, Chen X, Duvvuri U, Kim S, Liu A, Tabib T, Lafyatis R, Feng J, Gao SJ, Bruno TC, Vignali DAA, Lu X, Bao R, Vujanovic L, Ferris RL. Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing. Nat Commun. 2021 Dec 17;12(1):7338. doi: 10.1038/s41467-021-27619-4. PMID: 34921143.
Copy Download .nbib Format: NLM
Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing.

Nature communications

Kürten CHL, Kulkarni A, Cillo AR, Santos PM, Roble AK, Onkar S, Reeder C, Lang S, Chen X, Duvvuri U, Kim S, Liu A, Tabib T, Lafyatis R, Feng J, Gao SJ, Bruno TC, Vignali DAA, Lu X, Bao R, Vujanovic L, Ferris RL.
PMID: 34921143
Nat Commun. 2021 Dec 17;12(1):7338. doi: 10.1038/s41467-021-27619-4.

Head and neck squamous cell carcinoma (HNSCC) is characterized by complex relations between stromal, epithelial, and immune cells within the tumor microenvironment (TME). To enable the development of more efficacious therapies, we aim to study the heterogeneity, signatures of...

Cite
Kürten CHL, Kulkarni A, Cillo AR, et al. Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing. Nat Commun. 2021;12(1):7338doi: 10.1038/s41467-021-27619-4.
Kürten, C. H. L., Kulkarni, A., Cillo, A. R., Santos, P. M., Roble, A. K., Onkar, S., Reeder, C., Lang, S., Chen, X., Duvvuri, U., Kim, S., Liu, A., Tabib, T., Lafyatis, R., Feng, J., Gao, S. J., Bruno, T. C., Vignali, D. A. A., Lu, X., Bao, R., Vujanovic, L., & Ferris, R. L. (2021). Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing. Nature communications, 12(1), 7338. https://doi.org/10.1038/s41467-021-27619-4
Kürten, Cornelius H L, et al. "Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing." Nature communications vol. 12,1 (2021): 7338. doi: https://doi.org/10.1038/s41467-021-27619-4
Kürten CHL, Kulkarni A, Cillo AR, Santos PM, Roble AK, Onkar S, Reeder C, Lang S, Chen X, Duvvuri U, Kim S, Liu A, Tabib T, Lafyatis R, Feng J, Gao SJ, Bruno TC, Vignali DAA, Lu X, Bao R, Vujanovic L, Ferris RL. Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing. Nat Commun. 2021 Dec 17;12(1):7338. doi: 10.1038/s41467-021-27619-4. PMID: 34921143.
Copy Download .nbib Format: NLM
Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing.

Nature communications

Kürten CHL, Kulkarni A, Cillo AR, Santos PM, Roble AK, Onkar S, Reeder C, Lang S, Chen X, Duvvuri U, Kim S, Liu A, Tabib T, Lafyatis R, Feng J, Gao SJ, Bruno TC, Vignali DAA, Lu X, Bao R, Vujanovic L, Ferris RL.
PMID: 34921143
Nat Commun. 2021 Dec 17;12(1):7338. doi: 10.1038/s41467-021-27619-4.

Head and neck squamous cell carcinoma (HNSCC) is characterized by complex relations between stromal, epithelial, and immune cells within the tumor microenvironment (TME). To enable the development of more efficacious therapies, we aim to study the heterogeneity, signatures of...

Cite
Kürten CHL, Kulkarni A, Cillo AR, et al. Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing. Nat Commun. 2021;12(1):7338doi: 10.1038/s41467-021-27619-4.
Kürten, C. H. L., Kulkarni, A., Cillo, A. R., Santos, P. M., Roble, A. K., Onkar, S., Reeder, C., Lang, S., Chen, X., Duvvuri, U., Kim, S., Liu, A., Tabib, T., Lafyatis, R., Feng, J., Gao, S. J., Bruno, T. C., Vignali, D. A. A., Lu, X., Bao, R., Vujanovic, L., & Ferris, R. L. (2021). Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing. Nature communications, 12(1), 7338. https://doi.org/10.1038/s41467-021-27619-4
Kürten, Cornelius H L, et al. "Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing." Nature communications vol. 12,1 (2021): 7338. doi: https://doi.org/10.1038/s41467-021-27619-4
Kürten CHL, Kulkarni A, Cillo AR, Santos PM, Roble AK, Onkar S, Reeder C, Lang S, Chen X, Duvvuri U, Kim S, Liu A, Tabib T, Lafyatis R, Feng J, Gao SJ, Bruno TC, Vignali DAA, Lu X, Bao R, Vujanovic L, Ferris RL. Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing. Nat Commun. 2021 Dec 17;12(1):7338. doi: 10.1038/s41467-021-27619-4. PMID: 34921143.
Copy Download .nbib Format: NLM
Metabolic support of tumour-infiltrating regulatory T cells by lactic acid.

Nature

Watson MJ, Vignali PDA, Mullett SJ, Overacre-Delgoffe AE, Peralta RM, Grebinoski S, Menk AV, Rittenhouse NL, DePeaux K, Whetstone RD, Vignali DAA, Hand TW, Poholek AC, Morrison BM, Rothstein JD, Wendell SG, Delgoffe GM.
PMID: 33589820
Nature. 2021 Mar;591(7851):645-651. doi: 10.1038/s41586-020-03045-2. Epub 2021 Feb 15.

Regulatory T (T

Cite
Watson MJ, Vignali PDA, Mullett SJ, et al. Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature. 2021;591(7851):645-651doi: 10.1038/s41586-020-03045-2.
Watson, M. J., Vignali, P. D. A., Mullett, S. J., Overacre-Delgoffe, A. E., Peralta, R. M., Grebinoski, S., Menk, A. V., Rittenhouse, N. L., DePeaux, K., Whetstone, R. D., Vignali, D. A. A., Hand, T. W., Poholek, A. C., Morrison, B. M., Rothstein, J. D., Wendell, S. G., & Delgoffe, G. M. (2021). Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature, 591(7851), 645-651. https://doi.org/10.1038/s41586-020-03045-2
Watson, McLane J, et al. "Metabolic support of tumour-infiltrating regulatory T cells by lactic acid." Nature vol. 591,7851 (2021): 645-651. doi: https://doi.org/10.1038/s41586-020-03045-2
Watson MJ, Vignali PDA, Mullett SJ, Overacre-Delgoffe AE, Peralta RM, Grebinoski S, Menk AV, Rittenhouse NL, DePeaux K, Whetstone RD, Vignali DAA, Hand TW, Poholek AC, Morrison BM, Rothstein JD, Wendell SG, Delgoffe GM. Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature. 2021 Mar;591(7851):645-651. doi: 10.1038/s41586-020-03045-2. Epub 2021 Feb 15. PMID: 33589820; PMCID: PMC7990682.
Copy Download .nbib Format: NLM
Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function.

Nature communications

Kumar M, Molkentine D, Molkentine J, Bridges K, Xie T, Yang L, Hefner A, Gao M, Bahri R, Dhawan A, Frederick MJ, Seth S, Abdelhakiem M, Beadle BM, Johnson F, Wang J, Shen L, Heffernan T, Sheth A, Ferris RL, Myers JN, Pickering CR, Skinner HD.
PMID: 34732714
Nat Commun. 2021 Nov 03;12(1):6340. doi: 10.1038/s41467-021-26570-8.

Despite radiation forming the curative backbone of over 50% of malignancies, there are no genomically-driven radiosensitizers for clinical use. Herein we perform in vivo shRNA screening to identify targets generally associated with radiation response as well as those exhibiting...

Cite
Kumar M, Molkentine D, Molkentine J, et al. Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function. Nat Commun. 2021;12(1):6340doi: 10.1038/s41467-021-26570-8.
Kumar, M., Molkentine, D., Molkentine, J., Bridges, K., Xie, T., Yang, L., Hefner, A., Gao, M., Bahri, R., Dhawan, A., Frederick, M. J., Seth, S., Abdelhakiem, M., Beadle, B. M., Johnson, F., Wang, J., Shen, L., Heffernan, T., Sheth, A., Ferris, R. L., Myers, J. N., Pickering, C. R., & Skinner, H. D. (2021). Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function. Nature communications, 12(1), 6340. https://doi.org/10.1038/s41467-021-26570-8
Kumar, Manish, et al. "Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function." Nature communications vol. 12,1 (2021): 6340. doi: https://doi.org/10.1038/s41467-021-26570-8
Kumar M, Molkentine D, Molkentine J, Bridges K, Xie T, Yang L, Hefner A, Gao M, Bahri R, Dhawan A, Frederick MJ, Seth S, Abdelhakiem M, Beadle BM, Johnson F, Wang J, Shen L, Heffernan T, Sheth A, Ferris RL, Myers JN, Pickering CR, Skinner HD. Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function. Nat Commun. 2021 Nov 03;12(1):6340. doi: 10.1038/s41467-021-26570-8. PMID: 34732714; PMCID: PMC8566594.
Copy Download .nbib Format: NLM
Regulatory T Cell-Derived TRAIL Is Not Required for Peripheral Tolerance.

ImmunoHorizons

Dadey RE, Grebinoski S, Zhang Q, Brunazzi EA, Burton A, Workman CJ, Vignali DAA.
PMID: 33483333
Immunohorizons. 2021 Jan 22;5(1):48-58. doi: 10.4049/immunohorizons.2000098.

TRAIL (

Cite
Dadey RE, Grebinoski S, Zhang Q, et al. Regulatory T Cell-Derived TRAIL Is Not Required for Peripheral Tolerance. Immunohorizons. 2021;5(1):48-58doi: 10.4049/immunohorizons.2000098.
Dadey, R. E., Grebinoski, S., Zhang, Q., Brunazzi, E. A., Burton, A., Workman, C. J., & Vignali, D. A. A. (2021). Regulatory T Cell-Derived TRAIL Is Not Required for Peripheral Tolerance. ImmunoHorizons, 5(1), 48-58. https://doi.org/10.4049/immunohorizons.2000098
Dadey, Rebekah E, et al. "Regulatory T Cell-Derived TRAIL Is Not Required for Peripheral Tolerance." ImmunoHorizons vol. 5,1 (2021): 48-58. doi: https://doi.org/10.4049/immunohorizons.2000098
Dadey RE, Grebinoski S, Zhang Q, Brunazzi EA, Burton A, Workman CJ, Vignali DAA. Regulatory T Cell-Derived TRAIL Is Not Required for Peripheral Tolerance. Immunohorizons. 2021 Jan 22;5(1):48-58. doi: 10.4049/immunohorizons.2000098. PMID: 33483333; PMCID: PMC8663370.
Copy Download .nbib Format: NLM
Combination of a thioxodihydroquinazolinone with cisplatin eliminates ovarian cancer stem cell-like cells (CSC-LCs) and shows preclinical potential.

Oncotarget

Ma J, Salamoun J, Wipf P, Edwards R, Van Houten B, Qian W.
PMID: 29464053
Oncotarget. 2017 Dec 26;9(5):6042-6054. doi: 10.18632/oncotarget.23679. eCollection 2018 Jan 19.

Cancer stem cell-like cells (CSC-LCs) contribute to drug resistance and recurrence of ovarian cancer. Strategies that can eradicate CSC-LCs are expected to substantially improve the outcome of ovarian cancer treatment. We have previously identified a class of thioxodihydroquinazolinone small...

Cite
Ma J, Salamoun J, Wipf P, et al. Combination of a thioxodihydroquinazolinone with cisplatin eliminates ovarian cancer stem cell-like cells (CSC-LCs) and shows preclinical potential. Oncotarget. 2017;9(5):6042-6054doi: 10.18632/oncotarget.23679.
Ma, J., Salamoun, J., Wipf, P., Edwards, R., Van Houten, B., & Qian, W. (2018). Combination of a thioxodihydroquinazolinone with cisplatin eliminates ovarian cancer stem cell-like cells (CSC-LCs) and shows preclinical potential. Oncotarget, 9(5), 6042-6054. https://doi.org/10.18632/oncotarget.23679
Ma, Jing, et al. "Combination of a thioxodihydroquinazolinone with cisplatin eliminates ovarian cancer stem cell-like cells (CSC-LCs) and shows preclinical potential." Oncotarget vol. 9,5 (2018): 6042-6054. doi: https://doi.org/10.18632/oncotarget.23679
Ma J, Salamoun J, Wipf P, Edwards R, Van Houten B, Qian W. Combination of a thioxodihydroquinazolinone with cisplatin eliminates ovarian cancer stem cell-like cells (CSC-LCs) and shows preclinical potential. Oncotarget. 2017 Dec 26;9(5):6042-6054. doi: 10.18632/oncotarget.23679. eCollection 2018 Jan 19. PMID: 29464053; PMCID: PMC5814193.
Copy Download .nbib Format: NLM
Critical analysis of the potential for targeting STAT3 in human malignancy.

OncoTargets and therapy

Peyser ND, Grandis JR.
PMID: 23935373
Onco Targets Ther. 2013 Jul 30;6:999-1010. doi: 10.2147/OTT.S47903. Print 2013.

The signal transducer and activator of transcription (STAT) family of proteins was originally discovered in the context of normal cell biology where they function to transduce intracellular and extracellular signals to the nucleus, ultimately leading to transcription of specific...

Cite
Peyser ND, Grandis JR. Critical analysis of the potential for targeting STAT3 in human malignancy. Onco Targets Ther. 2013;6:999-1010doi: 10.2147/OTT.S47903.
Peyser, N. D., & Grandis, J. R. (2013). Critical analysis of the potential for targeting STAT3 in human malignancy. OncoTargets and therapy, 6999-1010. https://doi.org/10.2147/OTT.S47903
Peyser, Noah D, and Grandis, Jennifer R. "Critical analysis of the potential for targeting STAT3 in human malignancy." OncoTargets and therapy vol. 6 (2013): 999-1010. doi: https://doi.org/10.2147/OTT.S47903
Peyser ND, Grandis JR. Critical analysis of the potential for targeting STAT3 in human malignancy. Onco Targets Ther. 2013 Jul 30;6:999-1010. doi: 10.2147/OTT.S47903. Print 2013. PMID: 23935373; PMCID: PMC3735336.
Copy Download .nbib Format: NLM
Expression of Tim-3 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment.

Cell reports

Banerjee H, Nieves-Rosado H, Kulkarni A, Murter B, McGrath KV, Chandran UR, Chang A, Szymczak-Workman AL, Vujanovic L, Delgoffe GM, Ferris RL, Kane LP.
PMID: 34525351
Cell Rep. 2021 Sep 14;36(11):109699. doi: 10.1016/j.celrep.2021.109699.

Regulatory T cells (Treg cells) are critical mediators of self-tolerance, but they can also limit effective anti-tumor immunity. Although under homeostasis a small fraction of Treg cells in lymphoid organs express the putative checkpoint molecule Tim-3, this protein is...

Cite
Banerjee H, Nieves-Rosado H, Kulkarni A, et al. Expression of Tim-3 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment. Cell Rep. 2021;36(11):109699doi: 10.1016/j.celrep.2021.109699.
Banerjee, H., Nieves-Rosado, H., Kulkarni, A., Murter, B., McGrath, K. V., Chandran, U. R., Chang, A., Szymczak-Workman, A. L., Vujanovic, L., Delgoffe, G. M., Ferris, R. L., & Kane, L. P. (2021). Expression of Tim-3 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment. Cell reports, 36(11), 109699. https://doi.org/10.1016/j.celrep.2021.109699
Banerjee, Hridesh, et al. "Expression of Tim-3 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment." Cell reports vol. 36,11 (2021): 109699. doi: https://doi.org/10.1016/j.celrep.2021.109699
Banerjee H, Nieves-Rosado H, Kulkarni A, Murter B, McGrath KV, Chandran UR, Chang A, Szymczak-Workman AL, Vujanovic L, Delgoffe GM, Ferris RL, Kane LP. Expression of Tim-3 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment. Cell Rep. 2021 Sep 14;36(11):109699. doi: 10.1016/j.celrep.2021.109699. PMID: 34525351; PMCID: PMC8482289.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 41 entries